What we are doing about symptoms that can't be measured easily

Richert, John
February 2007
Inside MS;Feb/Mar2007, Vol. 25 Issue 1, p41
Academic Journal
The author reflects on issues related to the treatment of multiple sclerosis (MS). According to the author, the priorities of the National MS Society must be to learn how to evaluate convincingly the therapeutic potential of any treatment that might relieve troubling and disabling MS symptoms. He states that the National MS Society has convened a special task force to evaluate all of the evidence for the efficacy of marijuana for MS symptoms and all the evidence relating to adverse effects.


Related Articles

  • Getting Along with Your abcs. King, Martha // Inside MS;Fall99, Vol. 17 Issue 4, p20 

    Provides information on the use of the self-injectable drugs Avonex, Betaseron and Copaxone for people with relapsing forms of multiple sclerosis to reduce their number of attacks. Side effects of the drugs; Advantages; Limitations.

  • Side effect profile and adherence to in the treatment of Multiple Sclerosis with interferon beta-1a. Mohr, D.C.; Likosky, W.; Boudewyn, A.C.; Marietta, P.; Dwyer, P.; van der Wende, J.; Goodkin, D.E. // Multiple Sclerosis (13524585);Dec98, Vol. 4 Issue 6, p487 

    This study examines the course of patient-reported side effects during the first 4 months of treatment for multiple sclerosis (MS) with interferon beta-1a (IFN�-1a), and the relationship of those side effects to discontinuation of medication. Flu-like symptoms, muscle aches and chills...

  • Methylprednisolone.  // Reactions Weekly;Nov2014, Vol. 1524 Issue 1, p136 

    The article presents a case study of a woman who experienced acute global amnesia after treated with methylprednisolone for multiple sclerosis (MS) relapse instances.

  • Evaluation of flurbiprofen in detrusor instability. Cardozo, Linda D.; Stanton, Stuart L.; Robinson, Heather; Hole, David // British Medical Journal;2/2/1980, Vol. 280 Issue 6210, p281 

    Focuses on the evaluation of flurbiprofen in detrusor instability (idiopathic or secondary to multiple sclerosis) patients. Elimination of placebo factor and physician's in favor of the preparation in use by cross-over trials of drugs; Evidence of adverse reaction of drugs in patients;...

  • Mitoxantrone at low doses linked to cardiotoxicity in MS.  // Reactions Weekly;6/19/2010, Issue 1306, p5 

    The article discusses a research study on cardiotoxicity and other adverse effects linked with mitoxantrone treatment for multiple sclerosis (MS), published in the April 28, 2010 issue of the journal "Neurology."

  • Glatiramer acetate.  // Reactions Weekly;7/14/2012, Issue 1410, p24 

    The article describes the case of a 43-year-old man with relapsing-remitting multiple sclerosis who developed Guillain-Barre syndrome after receiving glatiramer acetate.

  • Fingolimod.  // Reactions Weekly;9/24/2011, Issue 1370, p20 

    The article describes the case of a 47-year-old woman who developed branch retinal vein occlusion while receiving fingolimod for multiple sclerosis.

  • Natalizumab.  // Reactions Weekly;9/24/2011, Issue 1370, p28 

    The article describes the case of a woman who developed immune thrombocytopenic purpura (ITP) while being treated with natalizumab for multiple sclerosis.

  • Methylprednisolone.  // Reactions Weekly;4/6/2013, Issue 1447, p28 

    The article presents a case study of a 30-year-old woman who developed acute cytolytic hepatitis during treatment with methylprednisolone for multiple sclerosis (MS).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics